gefitinib has been researched along with bp-1-102 in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (bp-1-102) | Trials (bp-1-102) | Recent Studies (post-2010) (bp-1-102) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 33 | 0 | 32 |
| Protein | Taxonomy | gefitinib (IC50) | bp-1-102 (IC50) |
|---|---|---|---|
| Signal transducer and activator of transcription 3 | Homo sapiens (human) | 6.8 | |
| Signal transducer and activator of transcription 3 | Mus musculus (house mouse) | 6.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Kong, L; Li, C; Li, S; Lin, JY; Liu, M; Luo, J; Sun, H; Xia, Y; Yang, L; Yu, K; Yu, W; Zhang, W | 1 |
1 other study(ies) available for gefitinib and bp-1-102
| Article | Year |
|---|---|
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line; Cell Line, Tumor; Female; Humans; MCF-7 Cells; Mice, Inbred ICR; Mice, Nude; Molecular Docking Simulation; Rats; STAT3 Transcription Factor | 2017 |